Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
Kumar, Shaji , Fonseca, Rafaël , Ketterling, Rhett P. , Dispenzieri, Angela , Lacy, Martha Q. , Hayman, Suzanne R. , Dingli, David , Knudson, Ryan A., Greenberg, Alexandra J. , Russell, Stephen J. , Zeldenrust, Steven R., Lust, John A., Kyle, Robert A. , Bergsagel, Leif, Rajkumar, S. Vincent , Bergsagel, P. Leif , Gertz, Morie A. , Buadi, Francis K. , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Ketterling, Rhett P , Fonseca, Rafael

Mayo Clinic

Blood | January 11, 2012 | Volume: 119 | Issue: 9 | Pages: 2100-2105

10.1182/blood-2011-11-390658 | PMID 22234687 Get It

Abstract Routine incorporation of FISH into multiple myeloma (MM) diagnostic testing has led to a better appreciation of the heterogeneity of genetic abnormalities associated with this disease. We studied a group of 484 patients with newly diagnosed symptomatic MM to better understand the prevalence of the various abnormalities and the prognostic significance of the overlapping abnormalities. A translocation involving the IgH locus and 1 of the 5 recurrent partner chromosomes was seen in 161 (33%) patients, and 275 (57%) had trisomy of at least 1 odd-numbered chromosome. High-risk FISH, defined as the presence of t(4;14), t(14;16), t(14;20), or loss of P53, was seen in 115 (24%) patients; the median overall survival for this group was 3.9 years, compared with “not reached” for standard-risk patients (P < .001). Among the patients with high-risk FISH, 49 patients who also had at least 1 trisomy had a median overall survival that was not reached, compared with 3 years for high-risk patients without a concurrent trisomy (P = .01). Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers.
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841
Franko, Jan , Shi, Qian , Goldman, Charles D., Pockaj, Barbara A. , Nelson, Garth D. , Goldberg, Richard M. , Pitot, Henry C., Sargent, Daniel J. , Grothey, Axel , Alberts, Steven R. , Sargent, Daniel J , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | December 13, 2011 | Volume: 30 | Issue: 3 | Pages: 263-267

10.1200/jco.2011.37.1039 | PMID 22162570 Get It

Purpose Symptoms and complications of metastatic colorectal cancer (mCRC) differ by metastatic sites. There is a paucity of prospective survival data for patients with peritoneal carcinomatosis colorectal cancer (pcCRC). We characterized outcomes of patients with pcCRC enrolled onto two prospective randomized trials of chemotherapy and contrasted that with other manifestations of mCRC (non-pcCRC). Methods A total of 2,095 patients enrolled onto two prospective randomized trials were evaluated for overall survival (OS) and progression-free survival (PFS). A Cox proportional hazard model was used to assess the adjusted associations. Results The characteristics of the pcCRC group (n = 364) were similar to those of the non-pcCRC patients in median age (63 v 61 years, P = .23), sex (57% males v 61%, P = .23), and performance status (Eastern Cooperative Oncology Group performance status 0 or 1 94% v 96%, P = .06), but differed in frequency of liver (63% v 82%, P < .001) and lung metastases (27% v 34%, P = .01). Median OS (12.7 v 17.6 months, hazard ratio [HR] = 1.3; 95% CI, 1.2 to 1.5; P < .001) and PFS (5.8 v 7.2 months, HR = 1.2; 95% CI, 1.1 to 1.3; P = .001) were shorter for pcCRC versus non-pcCRC. The unfavorable prognostic influence of pcCRC remained after adjusting for age, PS, liver metastases, and other factors (OS: HR = 1.3, P < .001; PFS: HR = 1.1, P = .02). Infusional fluorouracil, leucovorin, and oxaliplatin was superior to irinotecan, leucovorin, and fluorouracil as a first-line treatment among pcCRC (HR for OS = 0.62, P = .005) and non-pcCRC patients (HR = 0.66, P < .001). Conclusion pcCRC is associated with a significantly shorter OS and PFS as compared with other manifestations of mCRC. Future trials for mCRC should consider stratifying on the basis of pcCRC status.
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis
Kelley, James, Monach, Paul A. , Ji, Chuanyi, Zhou, Yebin , Wu, Jianming , Tanaka, Sumiaki, Mahr, Alfred , Johnson, Sharleen P , McAlear, Carol A. , Cuthbertson, David , Carette, Simon , Davis, John C. , Dellaripa, Paul F. , Hoffman, Gary S., Langford, Carol A. , Seo, Philip , Clair, E. William St. , Stone, John H., Ytterberg, Steven R. , Edberg, Jeffrey C., Kimberly, Robert P. , Khalidi, Nader , Specks, Ulrich , Spiera, Robert , Merkel, Peter A. , Mahr, Alfred , Monach, Paul A

Mayo Clinic

Proceedings of the National Academy of Sciences | December 7, 2011 | Volume: 108 | Issue: 51 | Pages: 20736-20741

10.1073/pnas.1109227109 | PMID 22147912 Get It

Granulomatosis with polyangiitis (Wegener's) is a rare autoimmune neutrophil-mediated vasculitis that can cause renal disease and mucosal manifestations. Antineutrophil cytoplasmic antibodies (ANCA) are present in many patients, vary in level over time, and induce neutrophil activation through engagement with Fc receptors (FcRs). Given roles for FcRs in ANCA-mediated neutrophil activation and IgA antibodies in mucosal immunity, we hypothesized that FcR genetics and previously unappreciated IgA ANCA affect clinical presentation. We assembled a total of 673 patients and 413 controls from two multicenter cohorts, performed ELISA and immunofluorescence assays to determine IgA and IgG ANCA positivity, and used Illumina, TaqMan, or Pyrosequencing to genotype eight haplotype-tagging SNPs in the IgA FcR ( FCAR ) and to determine NA1/NA2 genotype of FCGR3B, the most prevalent neutrophil IgG FcR. We evaluated neutrophil activation by measuring degranulation marker CD11b with flow cytometry or neutrophil extracellcular trap formation with confocal microscopy. Functional polymorphisms in FCGR3B and FCAR differed between patient groups stratified by renal involvement. IgA ANCA were found in ∼30% of patients and were less common in patients with severe renal disease. Neutrophil stimulation by IgA or IgG ANCA led to degranulation and neutrophil extracellcular trap formation in a FcR allele-specific manner (IgA:FCAR P = 0.008; IgG:FCGR3B P = 0.003). When stimulated with IgA and IgG ANCA together, IgG ANCA induced neutrophil activation was reduced ( P = 0.0001). FcR genotypes, IgA ANCA, and IgG ANCA are potential prognostic and therapeutic targets for understanding the pathogenesis and presentation of granulomatosis with polyangiitis (Wegener's).
TargetingPDGFR‐β in Cholangiocarcinoma
Fingas, Christian D., Mertens, Joachim C. , Razumilava, Nataliya , Bronk, Steven F., Sirica, Alphonse E. , Gores, Gregory J.

Mayo Clinic

Liver International | December 3, 2011 | Volume: 32 | Issue: 3 | Pages: 400-409

10.1111/j.1478-3231.2011.02687.x | PMID 22133064 Get It

AbstractBackgroundCholangiocarcinomas (CCAs) are highly desmoplastic neoplasms with a tumour microenvironment plentiful in myofibroblasts (MFBs).MFB‐derivedPDGF‐BBsurvival signalling is a mediator ofCCAcell resistance to apoptotic stimuli. This raises the concept that targetingPDGFR‐β, a cognate receptor ofPDGF‐BB, represents a potential strategy for the treatment of humanCCA.AimsHerein, we examine a role for inhibitingPDGFR‐β in restoringCCAcell sensitivity to apoptotic stimuliin vitroandin vivo.MethodsWe employed humanCCAsamples from 41 patients (19 intrahepatic and 22 extrahepaticCCAsamples), the humanCCAcell linesKMCH‐1 andHUCCT‐1 as well as shPDGFR‐β‐KMCH‐1 and human myofibroblasticLX‐2 cells for these studies.In vivo‐experiments were conducted using a syngeneic rat orthotopicCCAmodel.ResultsOf severalMFB‐derived growth factors profiled,PDGF‐BBandCTGFwere most abundantly expressed; however, onlyPDGF‐BBattenuated tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) cytotoxicity. Co‐culturingCCAcells withPDGF‐BB‐secretingMFBs significantly decreasedTRAIL‐inducedCCAcell apoptosis when compared with monoculture conditions; this cytoprotective effect was abrogated in the presence of the tyrosine kinase inhibitors imatinib mesylate or linifanib, which inhibitPDGFR‐β. Consistent with these findings,MFB‐imparted cytoprotection also was abolished whenPDGFR‐β was knocked down as demonstrated in shPDGFR‐β‐KMCH‐1 cells. Finally, administration of imatinib mesylate increasedCCAcell apoptosis and reduced tumour growth in a rodentin vivo‐CCAmodel that mimics the human disease.ConclusionsTargetingPDGFR‐β sensitizesCCAcells to apoptotic stimuli and appears to be therapeuticin vivo.
A 71-Year-Old Woman with Multiple Myeloma Status after Stem Cell Transplantation
Zeldenrust, Steven R., Murray, David , Katzmann, Jerry A., Donato, Leslie J.

Mayo Clinic

Clinical Chemistry | November 28, 2011 | Volume: 57 | Issue: 12 | Pages: 1645-1648

10.1373/clinchem.2011.163766 | PMID 22125317 Get It

Distribution and Associations of [−2]Proenzyme-Prostate Specific Antigen in Community Dwelling Black and White Men
Rhodes, Thomas , Jacobson, Debra J., McGree, Michaela E. , Sauver, Jennifer L. St. , Sarma, Aruna V. , Lieber, Michael M., Klee, George G., Demissie, Kitaw , Jacobsen, Steven J. , Girman, Cynthia J. , St Sauver, Jennifer L

Mayo Clinic

Journal of Urology | November 17, 2011 | Volume: 187 | Issue: 1 | Pages: 92-96

10.1016/j.juro.2011.09.060 | PMID 22093189 Get It

Benign Prostate Specific Antigen Distribution and Associations With Urological Outcomes in Community Dwelling Black and White Men
Rhodes, Thomas , Jacobson, Debra J., McGree, Michaela E. , Sauver, Jennifer L. St. , Sarma, Aruna V. , Lieber, Michael M., Klee, George G., Demissie, Kitaw , Jacobsen, Steven J. , Girman, Cynthia J. , St Sauver, Jennifer L

Mayo Clinic

Journal of Urology | November 17, 2011 | Volume: 187 | Issue: 1 | Pages: 87-91

10.1016/j.juro.2011.09.061 | PMID 22093190 Get It

Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy
Selcen, Duygu , Bromberg, Mark B. , Chin, Steven S. , Engel, Andrew G.

Mayo Clinic

Neurology | November 17, 2011 | Volume: 77 | Issue: 22 | Pages: 1951-1959

10.1212/wnl.0b013e31823a0ebe | PMID 22094483 Get It

Immunoglobulin D amyloidosis: a distinct entity
Hayman, Suzanne R. , Dingli, David , Dispenzieri, Angela , Greipp, Philip R., Kumar, Shaji , Lacy, Martha Q. , Lust, John A., Leung, Nelson , Rajkumar, S. Vincent , Russell, Stephen J. , Zeldenrust, Steven R., Kyle, Robert A. , Gertz, Morie A. , Buadi, Francis K. , Mıkhael, Joseph , Roy, Vivek , Rajkumar, S Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

Blood | November 8, 2011 | Volume: 119 | Issue: 1 | Pages: 44-48

10.1182/blood-2011-06-358895 | PMID 22065594 Get It

Abstract IgD monoclonal gammopathies are uncommon. They are seen rarely as a monoclonal gammopathy of undetermined significance and are present in 1%-2% of patients with multiple myeloma. In light-chain amyloidosis, IgD monoclonal proteins are found in ap-proximately 1% of patients. When an IgD monoclonal protein is found, amyloidosis is often omitted from the differential diagnosis. In the present study, we reviewed the natural history of IgD-associated amyloidosis among 53 patients seen over 41 years. The distribution of clinical syndromes suggests that these patients have a lower frequency of renal and cardiac involvement. The overall survival of these patients does not appear to be different from that of patients who have light-chain amyloidosis associated with another monoclonal protein.
Long-Term Outcomes of Proximal Row Carpectomy: A Minimum of 15-Year Follow-up
Ali, Mir H., Rizzo, Marco , Shin, Alexander Y. , Moran, Steven L. , Shin, Alexander Y

Mayo Clinic

HAND | November 3, 2011 | Volume: 7 | Issue: 1 | Pages: 72-78

10.1007/s11552-011-9368-y | PMID 23449142 Get It

Introduction Proximal row carpectomy (PRC) is a popular procedure for the treatment of wrist arthritis; however, the long-term clinical outcomes of this procedure are not well-characterized. The purpose of this study was to evaluate long-term results with PRC and to identify factors that may improve clinical outcomes. Methods A retrospective study was performed on all patients who underwent proximal row carpectomy between January 1967 and January 1992. Medical records and available radiographs were reviewed. The Disabilities of the Arm, Shoulder and Hand, and Patient Rated Wrist Exam, as well as hand motion diagrams were sent to all surviving patients. The contralateral extremity was used as a control. Data was analyzed using multivariant analysis and a Student's t test. Results Eighty-one patients underwent PRC. Average age at the time of surgery was 41 years. Average follow-up was 19.8 years. Sixty-one patients responded to the questionnaires. On final follow-up, wrist motion and grip strength were not significantly different from preoperative values. Radiographic follow-up beyond 2 years revealed joint narrowing and arthritic changes within the radiocapitate joint. Forty-six patients (74%) were not satisfied with the results of their surgery due to persistent pain or inability to return to previous occupational activities. Fifty-two patients required daily pain medication for wrist pain. Twelve patients had undergone a wrist arthrodesis. Conclusions Post-operative motion and grip strength values following PRC appear to remain stable over time. Surgical failure rates with conversion to wrist fusion occurred early within the post-operative follow-up. Many patients continued to complain of pain requiring daily medication and were unable to return to manual labor type jobs. The results of this study suggest that long-term patient satisfaction following PRC can be poor and the surgeon may wish to consider alternative treatment options for younger patients and those with high-demand jobs.